All In Biotech

Drug Trial Radar · NCT06949111

Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer(Neo-Color)

Efficacy and Safety of Conversion Therapy for pMMR/MSS T4M0 Colon Cancer Patients Treated With Radiotherapy and Systemic Therapy: a Prospective, Open-label, Multi-center, Randomized Controlled Trial(Neo-Color)

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

May 30, 2028

Study completion Mar 2030

Sponsor

Lead sponsor
Hebei Medical University Fourth HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage colon cancer. The main questions it aims to answer are: 1. Can the combination of radiotherapy and systemic treatment improve the R0 resection rate and complete response (CR) rate compared to chemotherapy alone? 2. Does this combination therapy enhance the tumor immune microenvironment, leading to better long-term outcomes? Researchers will compare the experimental group receiving concurrent chemoradiotherapy (CCRT) followed by 4 cycles of CAPOX + Iparomlimab and Tuvonralimab Injection with the control group receiving 4 cycles of CAPOX alone to see if the combination therapy offers superior efficacy. Participants will: 1. Undergo preoperative CCRT combined with one cycle of Iparomlimab and Tuvonralimab Injection, followed by 4 cycles of CAPOX + Iparomlimab and Tuvonralimab Injection in the experimental group. 2. Receive 4 cycles of CAPOX in the control group. 3. After the initial treatment regimen, surgical candidates will undergo surgery followed by an additional 4 cycles of CAPOX. Non-surgical candidates will continue with 4 more cycles of CAPOX, completing a total of 8 cycles. Efficacy will be re-evaluated after the completion of 8 cycles.

Conditions

  • Colon Cancer

Interventions

  • radiotherapyRadiation

    Radiotherapy: Administer three-dimensional conformal/intensity-modulated/TOMO radiotherapy with a conventional fractionation schedule of 36-41.4 Gy in 20-23 fractions (1.8 Gy per fraction).

  • CAPOXDrug

    4 cycles, Oxaliplatin 130 mg/m², Capecitabine 825 mg/m²

  • CapecitabineDrug

    Administer Capecitabine at a dose of 825 mg/m², twice daily, orally on radiotherapy days

  • Iparomlimab and Tuvonralimab InjectionDrug

    IV, 5 mg/kg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor Complete Response (CR) RateTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.